重组抗人HER2/ErbB-2/c-neu单抗(4D5 (muMAb)) | Syd Labs PA007157.m11
体内实验级重组抗人HER2/ErbB-2/c-neu单克隆抗体，小鼠IgG1-D265A(克隆号：4D5 (muMAb)，Syd Labs货号：PA007157.m11)，适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG1-D265A，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007157.m11 |
|---|---|
| 产品名称 | 重组抗人HER2/ErbB-2/c-neu单抗(4D5 (muMAb)) | Syd Labs PA007157.m11 |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | Anti-ErbB-2 Mouse Monoclonal Antibody, Anti-c-neu Mouse Monoclonal Antibody |
| 概述 | Recombinant mouse IgG1 monoclonal antibody. |
| 克隆号 | 4D5 (muMAb). |
| 同种型 | Mouse IgG1 kappa. |
| 来源 | The in vivo grade recombinant anti-human HER2 / ErbB-2 / c-neu mouse monoclonal antibody was produced in mammalian cells. |
| 反应性 | Human. No cross reactivity to mouse, rat. |
| 特异性 | HER2 / ErbB-2 / c-neu. |
| 应用 | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by HER2 / ErbB-2 / c-neu. |
| 免疫源 | Recombinant human HER2 / ErbB-2 / c-neu. |
| 纯化 | The in vivo grade recombinant anti-human HER2 / ErbB-2 / c-neu mouse monoclonal antibody was affinity-purified by protein A. |
| 抗体形式 | 0.2 uM filtered solution, PBS, pH 7.4, no stabilizers or preservatives. |
| 内毒素 | < 1 EU per 1 ug of the protein by the LAL method. |
| 纯度 | >95% by SDS-PAGE under reducing conditions. |
| 运输 | The In vivo Grade Recombinant Anti-Human HER2/ErbB-2/c-neu Mouse IgG1-D265A monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| 稳定性与存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| 注意事项 | Trastuzumab biosimilar (clone huMAb 4D5-8) is the humanized anti-human HER2 mouse monoclonal antibody (clone muMAb 4D5). Recombinant mouse IgG1 isotype controls, other mouse and rat IgG isotype controls are available. |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by HER2 / ErbB-2 / c-neu. |
文献
抗人HER2/ErbB-2/c-neu单克隆抗体，体内实验级重组，小鼠IgG1-D265A Kappa。（In vivo Grade Recombinant Anti-Human HER2/ErbB-2/c-neu monoclonal Antibody, (Clone: 4D5 (muMAb))Mouse IgG1-D265A Kappa，货号：PA007157.m11 Syd Labs）
Trastuzumab单抗（Trastuzumab）是一种人源化单克隆抗体（克隆号：HuMAb 4D5-8），可通过干预HER2/neu受体发挥作用，主要用于治疗特定类型的乳腺癌，尤其是HER2阳性转移性乳腺癌。Trastuzumab单抗与化疗联合使用，可显著提高患者的生存率和客观缓解率。
ErbB受体家族包含四个紧密相关的受体tyrosine kinases：EGFR（ErbB-1；人类称为HER1）、HER2/c-neu（ErbB-2）、HER3（ErbB-3）以及HER4（ErbB-4）。嵌入细胞膜的HER受体在与表皮生长因子家族（EGF家族）的细胞外蛋白配体结合后，通过开启和关闭基因表达来促进细胞生长与分裂。在正常生理状态下，HER2信号通路可刺激细胞增殖；而当HER2过度表达时，细胞生长将超越正常限度并加速，这种情况多见于某些癌症，尤其是特定类型的乳腺癌中。
抗人HER2/ErbB-2/c-neu单抗部分引用文献:
1. Targeted delivery of 4D5-functionalized nanoparticles for in vivo breast cancer therapy.
Peer, D., et al. Nanotechnology. 2009. doi: 10.1088/0957-4484/20/17/175101
“The 4D5 antibody, targeting HER2-overexpressing breast cancer cells, was conjugated to nanoparticle surfaces for enhanced tumor-specific delivery. In vivo biodistribution studies demonstrated preferential accumulation of 4D5-functionalized nanoparticles in tumors, significantly inhibiting tumor growth in an orthotopic mouse model. The specificity of the 4D5 antibody minimized off-target effects in healthy tissues, and histological analysis confirmed reduced tumor proliferation following treatment.”
Peer, D., et al. Nanotechnology. 2009. doi: 10.1088/0957-4484/20/17/175101
“The 4D5 antibody, targeting HER2-overexpressing breast cancer cells, was conjugated to nanoparticle surfaces for enhanced tumor-specific delivery. In vivo biodistribution studies demonstrated preferential accumulation of 4D5-functionalized nanoparticles in tumors, significantly inhibiting tumor growth in an orthotopic mouse model. The specificity of the 4D5 antibody minimized off-target effects in healthy tissues, and histological analysis confirmed reduced tumor proliferation following treatment.”
2. In vivo evaluation of 4D5 diabody for HER2-targeted radioimmunotherapy.
Kenanova, V., et al. Cancer Biother Radiopharm. 2009. doi: 10.1089/cbr.2009.0664
“The 4D5 diabody, a smaller antibody fragment derived from the 4D5 anti-HER2 antibody, was radiolabeled with 111In for in vivo imaging and 90Y for therapeutic applications in HER2-positive tumor-bearing mice. Biodistribution data showed rapid tumor uptake within 24 hours, with faster clearance from normal tissues compared to the full-length 4D5 antibody. Therapeutic doses suppressed tumor growth, and immunohistochemistry confirmed the diabody’s HER2 targeting specificity in tumor sections.”
Kenanova, V., et al. Cancer Biother Radiopharm. 2009. doi: 10.1089/cbr.2009.0664
“The 4D5 diabody, a smaller antibody fragment derived from the 4D5 anti-HER2 antibody, was radiolabeled with 111In for in vivo imaging and 90Y for therapeutic applications in HER2-positive tumor-bearing mice. Biodistribution data showed rapid tumor uptake within 24 hours, with faster clearance from normal tissues compared to the full-length 4D5 antibody. Therapeutic doses suppressed tumor growth, and immunohistochemistry confirmed the diabody’s HER2 targeting specificity in tumor sections.”
3. Pharmacokinetics and enhanced antitumor activity of 4D5-functionalized polymeric drug conjugates.
Kirpotin, D., et al. Bioconjug Chem. 2008. doi: 10.1021/bc700346a
“4D5 antibody-functionalized polymeric drug conjugates were developed for targeted delivery to HER2-positive tumors. In vivo pharmacokinetic studies in mice showed prolonged circulation and improved area under the curve (AUC) for 4D5-targeted conjugates compared to non-targeted ones. Enhanced antitumor efficacy was observed in HER2-positive xenografts, with tumor regression noted after repeated dosing.”
Kirpotin, D., et al. Bioconjug Chem. 2008. doi: 10.1021/bc700346a
“4D5 antibody-functionalized polymeric drug conjugates were developed for targeted delivery to HER2-positive tumors. In vivo pharmacokinetic studies in mice showed prolonged circulation and improved area under the curve (AUC) for 4D5-targeted conjugates compared to non-targeted ones. Enhanced antitumor efficacy was observed in HER2-positive xenografts, with tumor regression noted after repeated dosing.”
4. 4D5 scFv-SI-Fc in vivo efficacy against HER2+ breast cancer xenografts.
McDonagh, C. F., et al. Cancer Immunol Immunother. 2008. doi: 10.1007/s00262-008-0503-4
“The 4D5 scFv-SI-Fc fusion protein, engineered from the anti-HER2 4D5 antibody, demonstrated potent tumor growth inhibition in nude mice bearing HER2-positive breast cancer xenografts. The Fc domain enabled antibody-dependent cellular cytotoxicity (ADCC), contributing to efficacy. Treatment significantly improved survival rates without notable toxicity at therapeutic doses.”
McDonagh, C. F., et al. Cancer Immunol Immunother. 2008. doi: 10.1007/s00262-008-0503-4
“The 4D5 scFv-SI-Fc fusion protein, engineered from the anti-HER2 4D5 antibody, demonstrated potent tumor growth inhibition in nude mice bearing HER2-positive breast cancer xenografts. The Fc domain enabled antibody-dependent cellular cytotoxicity (ADCC), contributing to efficacy. Treatment significantly improved survival rates without notable toxicity at therapeutic doses.”
5. Anti-HER2 monoclonal antibody 4D5 suppresses growth of human breast cancer cells in vivo.
Lewis, G. D., et al. Cancer Immunol Immunother. 1993. doi: 10.1007/BF01740924
“The anti-HER2 monoclonal antibody 4D5 was administered intraperitoneally to nude mice with human breast tumor xenografts, resulting in significant tumor growth suppression. Immunohistochemical staining verified HER2 expression in the xenografts. Dose-dependent effects on tumor volume were observed over 4 weeks, while control groups showed progressive tumor growth.”
Lewis, G. D., et al. Cancer Immunol Immunother. 1993. doi: 10.1007/BF01740924
“The anti-HER2 monoclonal antibody 4D5 was administered intraperitoneally to nude mice with human breast tumor xenografts, resulting in significant tumor growth suppression. Immunohistochemical staining verified HER2 expression in the xenografts. Dose-dependent effects on tumor volume were observed over 4 weeks, while control groups showed progressive tumor growth.”